Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 9:44 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2449–2472 of 8,470 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Metabolism Disorder, Glucose Clear all

Conditions: Type 1 Diabetes Mellitus
Interventions: Anti-CD20 (rituximab), Placebo Comparator; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 8 Years to 45 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 13
States / cities: Los Angeles, California • San Francisco, California • Stanford, California + 10 more

Conditions: Pre Diabetes, Insulin Resistant
Interventions: salsalate, Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 30 Years to 60 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Stanford, California

Conditions: Obesity, Insulin Resistance
Interventions: Low glycemic index diet, Low fat diet, Very low carbohydrate diet; Other
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 18 Years to 40 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetes Mellitus, Type 1, Hyperlipidemias
Interventions: Colesevelam HCl, Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 65 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Diabetes Mellitus, Type 2, HFpEF - Heart Failure With Preserved Ejection Fraction
Interventions: Semaglutide, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 58,387 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetes Mellitus, Congestive Heart Failure, Arthritis, COPD, Depression
Interventions: Homing in on Health; Behavioral
Lead sponsor: Agency for Healthcare Research and Quality (AHRQ); Federal
Eligibility: 40 Years and older
Enrollment: 415 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Metabolic Syndrome
Interventions: Blackberries, Control; Other
Lead sponsor: Janet Novotny; Federal
Eligibility: 25 Years to 75 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Beltsville, Maryland

Conditions: Schizophrenia, Metabolic Syndrome, Vitamin D Deficiency
Interventions: Blood Draw; Other
Lead sponsor: Creighton University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Type 1 Diabetes Mellitus
Interventions: Artificial Pancreas Control Software; Device
Lead sponsor: Legacy Health System; Other
Eligibility: 21 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Maternal Hypoglycemia
Interventions: Not listed
Lead sponsor: Oklahoma State University Center for Health Sciences; Other
Eligibility: Up to 35 Years · Female only
Enrollment: 350 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Tulsa, Oklahoma

Conditions: Hypertension, Insulin Resistance
Interventions: Para-aminohippuric Acid, Angiotensin II, Norepinephrine; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Systemic Lupus Erythematosus, Insulin Resistance, Atherosclerosis
Interventions: Not listed
Lead sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); NIH
Eligibility: 30 Years to 55 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetes Mellitus, Type 2, Metformin Adverse Reaction
Interventions: Metformin, Placebo; Drug
Lead sponsor: St. Louis University; Other
Eligibility: 40 Years to 70 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: T2DM (Type 2 Diabetes Mellitus)
Interventions: Group Emotion Focused Behavioral Intervention (G-EFBI), Group - With Every Heartbeat is Life (G-WEHL); Behavioral
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: PreDiabetes
Interventions: PAC with HEPA filter intact, PAC with HEPA filter removed; Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 85 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetic Foot Ulcers
Interventions: ATG002 (study drug); Drug
Lead sponsor: CoMentis; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 13
States / cities: Homewood, Alabama • Phoenix, Arizona • Tucson, Arizona + 10 more

Conditions: Diabetes Mellitus, Type 2
Interventions: TAK-875, TAK-875 Placebo, Glimepiride; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 38
States / cities: Muscle Shoals, Alabama • Phoenix, Arizona • Fresno, California + 35 more

Conditions: Diabetes
Interventions: Not listed
Lead sponsor: Eastern Virginia Medical School; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Hyperglycemia, Hypertension
Interventions: AVACEN 100, AVACEN 100 Heat Only, AVACEN Sham; Device
Lead sponsor: Jeff Moore; Other
Eligibility: 18 Years to 40 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: San Diego, California

Conditions: Cardiovascular Risk Factor, Prediabetes, Overweight and Obesity, Sedentary Behavior
Interventions: The Physical Activity for The Heart (PATH) intervention, Be Active Your Way Booklet; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 40 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Beaver Falls, Pennsylvania • Pittsburgh, Pennsylvania

Conditions: Diabetes Mellitus
Interventions: Office Staff Support, Peer Support, Usual Care Support, Educator Support; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 80 Years
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 2
States / cities: Hershey, Pennsylvania • Pittsburgh, Pennsylvania

Conditions: Polycystic Ovary Syndrome
Interventions: metformin, exenatide or combined (metformin & exenatide ); Drug
Lead sponsor: Metabolic Center of Louisiana Research Foundation; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Sleep Disturbance, Postmenopausal Symptoms, Insulin Sensitivity, Cardiovascular Risk Factor
Interventions: Sleep Restriction, Habitual Sleep; Behavioral
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: Female only
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Diabetes Mellitus, Type 1
Interventions: Insulin lispro, recombinant human hyaluronidase PH20, Insulin aspart, Insulin glulisine, Insulin glargine; Drug
Lead sponsor: Halozyme Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 19
States / cities: Escondido, California • La Jolla, California • San Mateo, California + 16 more

Search by objective public record fields.

Rituximab in New Onset Type 1 Diabetes

Beneficial Effect of Salicylates: Insulin Action, Secretion or Clearance?

Popular Diets Study

Efficacy of Colesevelam in Subjects With Type 1 Diabetes Mellitus

Emulation of the STEP-HFpEF DM Heart Failure Trial in Healthcare Claims Data

Homing in on Health: Study of a Home Delivered Chronic Disease Self Management Program

Blackberry Flavonoid Absorption and Effects on Intestinal Bacteria

The Influence of Vitamin D on Atypical Antipsychotic-induced Weight Gain

Artificial Pancreas Control System in an Outpatient Setting

Maternal Hypoglycemia and Placental Pathology

Caveolin-1 and Vascular Dysfunction

Insulin Resistance and Atherosclerosis in Women With Lupus

Metformin Gastrointestinal Intolerance: Measurement of Mitochondrial Complex I

Group Emotion-Focused Behavioral Intervention for Diabetes Distress/A1c in T2D.

Cleaner Air for Lower Cardiometabolic Risk

Safety and Preliminary Efficacy Study of Nicotine Gel to Treat Diabetic Foot Ulcers

Comparison of TAK-875 to Placebo as an Add-on to Glimepiride in Patients With Type 2 Diabetes

Ultrasound Findings in Diabetic Pregnancies

AVACEN Hand Heating on Fasting Blood Glucose

Active You: A Novel Exercise Program for African Americans

Program Reinforcement Impacts Self Management (PRISM)

Exenatide and Metformin Therapy in Overweight Women With PCOS

Effect of Sleep Restriction on Adipose Tissue and Skeletal Muscle Insulin Sensitivity

Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus